BioXcel Therapeutics (BTAI) News Today $4.98 -0.25 (-4.78%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.00 +0.02 (+0.42%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Bioxcel Therapeutics Files Prospectus for $80M Share SaleAugust 21 at 2:39 AM | theglobeandmail.comAnalysts Set BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Target Price at $39.75August 21 at 2:17 AM | americanbankingnews.comBioxcel Therapeutics (BTAI) Receives a Buy from Canaccord GenuityAugust 20 at 4:21 PM | theglobeandmail.comBioXcel Therapeutics announces pre-sNDA meeting responses from FDAAugust 19, 2025 | msn.comBioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaAugust 19, 2025 | globenewswire.comBioXcel stock surges after positive FDA feedback on BXCL501 expansionAugust 18, 2025 | investing.comBioXcel Shares Jump After Encouraging FDA Feedback on BXCL501 Home-Use ExpansionAugust 18, 2025 | msn.comBioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or SchizophreniaAugust 18, 2025 | globenewswire.comBioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label (This works)August 18, 2025 | msn.comBioXcel Therapeutics (NASDAQ:BTAI) Price Target Raised to $10.00August 17, 2025 | americanbankingnews.comBioXcel Therapeutics price target raised to $10 from $8 at H.C. WainwrightAugust 15, 2025 | msn.comBioXcel Therapeutics Receives Positive FDA FeedbackAugust 15, 2025 | msn.comBioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” SeriesAugust 13, 2025 | globenewswire.comBioXcel Therapeutics Raises $30.4M, Meets Financing CovenantAugust 12, 2025 | theglobeandmail.comBioXcel Therapeutics trading resumesAugust 12, 2025 | msn.comBioXcel Therapeutics trading halted, volatility trading pauseAugust 12, 2025 | msn.comBioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business UpdatesAugust 12, 2025 | globenewswire.comBioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth ConferenceAugust 11, 2025 | globenewswire.comMizuho Securities Keeps Their Hold Rating on Bioxcel Therapeutics (BTAI)August 9, 2025 | theglobeandmail.comBioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in ...August 6, 2025 | finance.yahoo.comBioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical StudiesAugust 6, 2025 | globenewswire.comBioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaAugust 1, 2025 | globenewswire.comBioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®July 21, 2025 | globenewswire.comBioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial ProgressJuly 11, 2025 | insidermonkey.comBioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial ProgressJuly 11, 2025 | msn.comBioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial ... - MorningstarJuly 2, 2025 | morningstar.comMBioXcel Therapeutics Receives Positive DSMB Recommendation to Continue SERENITY At-Home Phase 3 Trial for BXCL501 - NasdaqJuly 2, 2025 | nasdaq.comBioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation...July 1, 2025 | markets.businessinsider.comBioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaJuly 1, 2025 | globenewswire.comBTAI - BioXcel Therapeutics Inc Trailing Returns - MorningstarJune 27, 2025 | morningstar.comMBioXcel Therapeutics, Inc. (BTAI) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comBioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of ...May 29, 2025 | morningstar.comMBioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaMay 27, 2025 | globenewswire.comBioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing RequirementMay 27, 2025 | globenewswire.comBank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI)May 15, 2025 | theglobeandmail.comBioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comBank of America Securities Keeps Their Sell Rating on Bioxcel Therapeutics (BTAI)March 28, 2025 | markets.businessinsider.comBioXcel Therapeutics price target lowered to $1 from $4 at BofAMarch 28, 2025 | markets.businessinsider.comBioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024March 27, 2025 | globenewswire.comRodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy RecommendationMarch 20, 2025 | msn.comBioXcel Therapeutics initiated with a Buy at Rodman & RenshawMarch 19, 2025 | markets.businessinsider.comBioXcel Therapeutics strengthens cash position to advance SERENITY trialMarch 11, 2025 | markets.businessinsider.comBioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaMarch 11, 2025 | globenewswire.comBioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trialMarch 7, 2025 | markets.businessinsider.comBioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaMarch 7, 2025 | globenewswire.comBofA maintains BioXcel Therapeutics stock underperform ratingMarch 5, 2025 | uk.investing.comBioXcel Therapeutics Announces Closing of $14 Million Registered Direct OfferingMarch 4, 2025 | globenewswire.comBioXcel Therapeutics announces $14M registered direct offeringMarch 4, 2025 | markets.businessinsider.comBioXcel Therapeutics Announces $14 Million Registered Direct OfferingMarch 3, 2025 | globenewswire.comBioXcel Shares Are Up Today: What's Going On?March 3, 2025 | benzinga.com Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address BTAI Media Mentions By Week BTAI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BTAI News Sentiment▼0.480.66▲Average Medical News Sentiment BTAI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BTAI Articles This Week▼102▲BTAI Articles Average Week Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Citius Oncology News Climb Bio News ALT5 Sigma News Alpha Cognition News Inhibikase Therapeutics News Compugen News Scilex News Fate Therapeutics News Protalix BioTherapeutics News Coherus Oncology News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BTAI) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access